Bionovo Discovers New Estrogen Regulatory Elements For Breast Cancer And Osteoporosis Drugs
Bionovo Inc. (Nasdaq: BNVI) announced results on the role of estrogen regulatory elements important in developing drugs for breast cancer and osteoporosis. The data, which were presented at the Endocrine Society's 90th Annual Meeting, showed that the new regulatory elements are essential for the differentiation of the estrogenic pharmacological activity exerted by different compounds.
Men Treated For Prostate Cancer Experience High Levels Of Psychological Distress After Treatment
Men treated for prostate cancer have high levels of psychological distress and many suffer ongoing sexual dysfunction and lower urinary tract symptoms, according to a survey of men in England designed to explore their supportive care needs. Prostate cancer is the commonest solid cancer in men, accounting for one in every four cancers diagnosed in males in England in 2004.
New Analysis Shows That REVLIMID reg; Plus Dexamethasone Yielded A Mean Survival Of 5.6 Years For Patients With Multiple Myeloma
Celgene Corporation (NASDAQ: CELG) has announced that according to data from a pooled study presented at the 13th European Hematology Association (EHA) congress in Copenhagen, Denmark, multiple myeloma patients taking REVLIMID (lenalidomide) plus dexamethasone significantly increased their survival rates.
Accumetrics Announces The Launch And First Patient Enrolled Into The GRAVITAS Trial
Patient enrollment into the GRAVITAS (Gauging Responsiveness With A VerifyNow(R) Assay-Impact On Thrombosis And Safety) trial has begun, officials from Accumetrics announced.
ADVENTRX Announces CoFactor R Phase 2b Clinical Trial Overall Survival Results
ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) provided an update with regard to overall survival from its Phase 2b clinical trial of CoFactor for the treatment of first-line metastatic colorectal cancer.
Exelixis Reaches Agreement With FDA On Special Protocol Assessment For XL184 Phase 3 Trial
Exelixis, Inc. (Nasdaq: EXEL) announced that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3 registration trial of XL184, a small molecule anticancer compound targeting MET, RET, and VEGFR2, via the Special Protocol Assessment process.
Blood Pressure Lowering Effect Of Hypertension Treatment Device Further Validated In New Studies
European Society of Hypertension -- Booth # 21, Hall 15.1 -- InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), announced the findings of new studies and analysis highlighting RESPeRATE -- the only medical device cleared by the FDA and CE-approved for the treatment of hypertension.
Sensitivity Enhancements To Monogram's Trofile TM Assay Demonstrate Improved Power To Select Patients For CCR5 Antagonist Therapy
Monogram Biosciences, Inc. (Nasdaq: MGRM) announced that data related to the enhanced performance of the company's HIV tropism assay were presented in an oral presentation at the 17th International HIV Drug Resistance Workshop in Sitges, Spain.
Metabolex Completes Patient Enrollment In Phase 2 Trial Of MBX-8025 For Treatment Of Dyslipidemia
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has completed enrollment in a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides.
FDA Approves Cymbalta R For The Management Of Fibromyalgia
The U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder, Eli Lilly and Company (NYSE: LLY) announced. Cymbalta is the first serotonin- norepinephrine reuptake inhibitor with proven efficacy for reducing pain in patients with fibromyalgia.